Navigation Links
CLAAD Lauds Signature Therapeutics' R&D Efforts To Reduce Prescription Drug Abuse
Date:7/12/2013

WASHINGTON, July 12, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) praised Signature Therapeutics, Inc. today for taking a national lead in biopharmaceutical research and development to reduce prescription drug abuse. Signature Therapeutics is a privately held company developing next-generation abuse-deterrent prescription medications. 

More than 2.7 percent of the U.S. population currently abuses prescription drugs.[1] In 2010, prescription drug overdoses took the lives of 22,134 Americans.[2] Since 2009, CLAAD has called for private-sector research into novel technologies to reduce prescription drug abuse. 

Michael Barnes, executive director of CLAAD, said, "Signature Therapeutics has distinguished itself in a growing market for safer medications by thinking big."

Signature Therapeutics is creating novel innovations, including "prodrugs," which would resist common methods of drug abuse, such as melting and injecting, crushing and snorting, or chewing before swallowing.  The company's pills are designed to be bioactivated, meaning that when taken by mouth, enzymes in the gastrointestinal tract trigger the release of the active ingredient.  Administered in any other way, a pill would not produce euphoria or any other significant effect.

Signature Therapeutics intends to apply its prodrug technology beyond opioids to other classes of commonly abused medications that lack safety features, such as stimulants used to treat attention-deficit disorder. Opioid pain relievers are the most commonly abused prescription drugs, but the abuse of tranquilizers, stimulants, and sedatives is also harmful and prevalent.[3]  In 2011, the anti-anxiety medication alprazolam was the most commonly found drug in overdose cases in Georgia, according to an analysis of autopsies.[4]  A study at the University of Kentucky found that out of 1,811 undergraduates, 34 percent reported improper use of stimulants.[5]

"Signature Therapeutics is the only company that I am aware of that is developing abuse-deterrent medications in a variety of drug classes," Barnes said.

Wes Sterman, CEO of Signature Therapeutics, said, "We are thrilled that CLAAD has recognized our commitment to raising the bar for abuse resistance."

About the Center for Lawful Access and Abuse Deterrence
CLAAD coordinates efforts to prevent prescription drug fraud, diversion, and abuse while advancing patient access to high-quality medical care. Follow @claad_coalition.

About Signature Therapeutics, Inc.
Signature Therapeutics is a privately-held biopharmaceutical company focused on creating best-in-class abuse-resistant prescription medications.


[1] http://www.drugabuse.gov/publications/topics-in-brief/prescription-drug-abuse
[2] http://www.cdc.gov/media/releases/2013/p0220_drug_overdose_deaths.html
[3] http://www.drugabuse.gov/publications/topics-in-brief/prescription-drug-abuse
[4] http://www.mcduffieprogress.com/article_4607.shtml
[5] http://www.schumer.senate.gov/record.cfm?id=344041  


'/>"/>
SOURCE CLAAD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CLAAD Petitions FDA To Reject Opioid Medications Without Safety Features
2. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
3. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
4. CLAAD Recognizes The Locking Cap as Top 5 Technology To Reduce Rx Abuse
5. CLAAD Recognizes SMART/Script as Top 5 Technology To Reduce Rx Abuse
6. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
7. CLAAD Names Eagle Advancement Institute as Honoree of Top 5 Technologies To Reduce Prescription Drug Abuse
8. CLAAD Warns of Increase in Prescription Drug Overdoses
9. CHPA Applauds Pennsylvanias Adoption of Real-Time, Stop-Sale Technology, An Effective Tool in the Fight Against Methamphetamine
10. PPTA Applauds Preserving Access to Orphan Drugs Acts
11. CHPA Lauds Vermonts Adoption of HB 522
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), today announced that it has reached ... holder and largest shareholder, to modify its existing credit ... to the modification, WAVI agreed to exchange its existing ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... ... it will be exhibiting and providing demos of its smart journaling platform at ... Convention Center in Washington D.C. from August 3-6, 2017. , The APA Annual ...
(Date:7/25/2017)... ... July 25, 2017 , ... Nautilus ... United States, today announced its partnership with financial technology company, Automated Transaction Delivery ... of the solution lies within Hyosung’s superior ATMs, assisted self-service devices and associated ...
(Date:7/25/2017)... ... July 25, 2017 , ... Facing medical needs with a newborn boy this ... of a new benefit for employees that is uncommon in American business: 12 weeks ... supports me and other employees as new parents. It keeps our family life more ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
(Date:7/24/2017)... JACKSONVILLE, Florida (PRWEB) , ... ... ... Klaproth, Division Marketing Director,      (407) 916-7235, kklaproth(at)robinsmorton(dot)com , Robins ... guests joined together to celebrate the structural topping out of the new ...
Breaking Medicine News(10 mins):